JAKSON

JAKSON – Selective JAK/ROCK kinases inihibitor in treatment of immune-mediated diseases

The main objective of the project is designing an innovative, orally administered targeted drug for treatment of immune-mediated diseases which will be far more active and safe than those currently offered on the market as well as will offer an alternative to patients resistant to standard treatment.

Total cost of the JAKSON project: 32 733 402,67 PLN
Total value of funding:  PLN 21,687080.32